Table 1 Characteristics of the included patients with first primary kidney cancer
Characteristics | Group 1 (Alive) | Group 2 (CCD) | Group 3 (KCD) | Group 4 (OE) | p-value |
|---|---|---|---|---|---|
Age at diagnosis |  |  |  |  | < 0.001 |
 1–50 | 8366 (25.74%) | 156 (5.05%) | 316 (9.84%) | 453 (7.18%) |  |
 51–58 | 8512 (26.19%) | 369 (11.95%) | 577 (17.96%) | 838 (13.28%) |  |
 59–65 | 6804 (20.93%) | 475 (15.39%) | 591 (18.4%) | 1091 (17.28%) |  |
 66–73 | 5544 (17.06%) | 687 (22.25%) | 635 (19.77%) | 1480 (23.45%) |  |
 over 75 | 3280 (10.09%) | 1400 (45.35%) | 1093 (34.03%) | 2450 (38.81%) |  |
Marital status |  |  |  |  | < 0.001 |
 Sinlge/divorce/widow | 10,464 (32.19%) | 1442 (46.71%) | 1322 (41.16%) | 2833 (44.88%) |  |
 Marry | 22,042 (67.81%) | 1645 (53.29%) | 1890 (58.84%) | 3479 (55.12%) |  |
Race |  |  |  |  | < 0.001 |
 White | 26,784 (82.40%) | 2482 (80.40%) | 2670 (83.13%) | 5219 (0.10%) |  |
Asian/Pacific Islander | 1701 (5.23%) | 112 (3.63%) | 163 (5.07%) | 224 (3.55%) | Â |
 Black | 3759 (11.56%) | 474 (15.35%) | 352 (10.96%) | 809 (12.82%) |  |
 American Indian/Alaska Native | 262 (0.81%) | 19 (0.62%) | 27 (0.84%) | 60 (0.95%) |  |
Sex |  |  |  |  | < 0.001 |
 Female | 12,938 (39.8%) | 1159 (37.54%) | 1177 (36.64%) | 2385 (37.79%) |  |
 Male | 19,568 (60.2%) | 1928 (62.46%) | 2035 (63.36%) | 3927 (62.21%) |  |
T (AJCC 6th) |  |  |  |  | < 0.001 |
 I | 28,286 (87.02%) | 2668 (86.43%) | 2039 (63.48%) | 5398 (85.52%) |  |
 II | 4220 (12.98%) | 419 (13.57%) | 1173 (36.52%) | 914 (14.48%) |  |
N (AJCC 6th) |  |  |  |  | < 0.001* |
 0 | 32,389 (99.64%) | 3063 (99.22%) | 2992 (93.15%) | 6233 (98.75%) |  |
 I | 86 (0.26%) | 21 (0.68%) | 151 (4.7%) | 64 (1.01%) |  |
 II | 31 (0.10%) | 3 (0.10%) | 69 (2.15%) | 15 (0.24%) |  |
M (AJCC 6th) |  |  |  |  | < 0.001 |
 0 | 32,506 (100%) | 3087 (100%) | 3212 (100%) | 6312 (100%) |  |
 I | 0 | 0 | 0 | 0 |  |
Tumour size |  |  |  |  | < 0.001 |
  ≤ 3 cm | 13,379 (41.16%) | 1057 (32.24%) | 492 (15.32%) | 2182 (34.57%) |  |
 >3 cm | 19,127 (58.84%) | 2030 (65.76%) | 2720 (84.68%) | 4130 (65.43%) |  |
Radiation therapy |  |  |  |  | < 0.001* |
 No received | 32,457 (99.85%) | 3064 (99.25%) | 3126 (97.32%) | 6280 (99.49%) |  |
 Received | 49 (0.15%) | 23 (0.75%) | 86 (2.68%) | 32 (0.51%) |  |
Chemotherapy |  |  |  |  | < 0.001* |
 No received | 32,367 (99.57%) | 3071 (99.48%) | 3048 (94.89%) | 6252 (99.05%) |  |
 Received | 139 (0.43%) | 16 (0.52%) | 164 (5.11%) | 60 (0.95%) |  |
Scope of lymph node |  |  |  |  | < 0.001 |
 None | 30,254 (93.07%) | 2910 (94.27%) | 2759 (85.9%) | 5908 (93.6%) |  |
 1–3 regional lymph nodes removed | 1466 (4.51%) | 131 (4.24%) | 299 (9.31%) | 756 (4.40%) |  |
 4 or more regional lymph nodes removed | 786 (2.42%) | 46 (1.49%) | 154 (4.79%) | 19,738 (2.00%) |  |
Surgey of primary site |  |  |  |  | < 0.001 |
 No operation | 773 (2.38%) | 517 (16.75%) | 606 (18.87%) | 944 (14.96%) |  |
 Local tumour destruction/excision | 1555 (4.78%) | 202 (6.54%) | 101 (3.14%) | 440 (6.97%) |  |
 partly nephrectomy | 13,940 (42.88%) | 857 (27.76%) | 611 (19.02%) | 1809 (28.66%) |  |
 total nephrectomy | 16,238 (49.95%) | 1511 (48.95%) | 1894 (58.97%) | 3119 (49.41%) |  |